Ricardo Araya1, Paulo Rossi Menezes2,3, Heloísa Garcia Claro2,4, Lena R Brandt5, Kate L Daley2, Julieta Quayle2, Francisco Diez-Canseco5, Tim J Peters6, Daniela Vera Cruz2, Mauricio Toyama5, Suzana Aschar2, Liliana Hidalgo-Padilla5, Hellen Martins2, Victoria Cavero5, Thais Rocha2, George Scotton2, Ivan F de Almeida Lopes7, Mark Begale8, David C Mohr8, J Jaime Miranda5,9. 1. Centre for Global Mental Health, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, United Kingdom. 2. Population Mental Health Research Centre, Universidade de São Paulo, São Paulo, Brazil. 3. Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. 4. School of Nursing, Universidade Estadual de Campinas, Campinas, Brazil. 5. CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru. 6. Bristol Medical School, Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom. 7. Federal University of ABC, Engineering, Modeling and Applied Social Sciences Center (CECS), Santo André, Brazil. 8. Center for Behavioral Intervention Technologies, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 9. Department of Medicine, School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.
Abstract
Importance: Depression is a leading contributor to disease burden globally. Digital mental health interventions can address the treatment gap in low- and middle-income countries, but the effectiveness in these countries is unknown. Objective: To investigate the effectiveness of a digital intervention in reducing depressive symptoms among people with diabetes and/or hypertension. Design, Setting, and Participants: Participants with clinically significant depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] score ≥10) who were being treated for hypertension and/or diabetes were enrolled in a cluster randomized clinical trial (RCT) at 20 sites in São Paulo, Brazil (N=880; from September 2016 to September 2017; final follow-up, April 2018), and in an individual-level RCT at 7 sites in Lima, Peru (N=432; from January 2017 to September 2017; final follow-up, March 2018). Interventions: An 18-session, low-intensity, digital intervention was delivered over 6 weeks via a provided smartphone, based on behavioral activation principles, and supported by nurse assistants (n = 440 participants in 10 clusters in São Paulo; n = 217 participants in Lima) vs enhanced usual care (n = 440 participants in 10 clusters in São Paulo; n = 215 participants in Lima). Main Outcomes and Measures: The primary outcome was a reduction of at least 50% from baseline in PHQ-9 scores (range, 0-27; higher score indicates more severe depression) at 3 months. Secondary outcomes included a reduction of at least 50% from baseline PHQ-9 scores at 6 months. Results: Among 880 patients cluster randomized in Brazil (mean age, 56.0 years; 761 [86.5%] women) and 432 patients individually randomized in Peru (mean age, 59.7 years; 352 [81.5%] women), 807 (91.7%) in Brazil and 426 (98.6%) in Peru completed at least 1 follow-up assessment. The proportion of participants in São Paulo with a reduction in PHQ-9 score of at least 50% at 3-month follow-up was 40.7% (159/391 participants) in the digital intervention group vs 28.6% (114/399 participants) in the enhanced usual care group (difference, 12.1 percentage points [95% CI, 5.5 to 18.7]; adjusted odds ratio [OR], 1.6 [95% CI, 1.2 to 2.2]; P = .001). In Lima, the proportion of participants with a reduction in PHQ-9 score of at least 50% at 3-month follow-up was 52.7% (108/205 participants) in the digital intervention group vs 34.1% (70/205 participants) in the enhanced usual care group (difference, 18.6 percentage points [95% CI, 9.1 to 28.0]; adjusted OR, 2.1 [95% CI, 1.4 to 3.2]; P < .001). At 6-month follow-up, differences across groups were no longer statistically significant. Conclusions and Relevance: In 2 RCTs of patients with hypertension or diabetes and depressive symptoms in Brazil and Peru, a digital intervention delivered over a 6-week period significantly improved depressive symptoms at 3 months when compared with enhanced usual care. However, the magnitude of the effect was small in the trial from Brazil and the effects were not sustained at 6 months. Trial Registration: ClinicalTrials.gov: NCT02846662 (São Paulo) and NCT03026426 (Lima).
Importance: Depression is a leading contributor to disease burden globally. Digital mental health interventions can address the treatment gap in low- and middle-income countries, but the effectiveness in these countries is unknown. Objective: To investigate the effectiveness of a digital intervention in reducing depressive symptoms among people with diabetes and/or hypertension. Design, Setting, and Participants: Participants with clinically significant depressive symptoms (Patient Health Questionnaire-9 [PHQ-9] score ≥10) who were being treated for hypertension and/or diabetes were enrolled in a cluster randomized clinical trial (RCT) at 20 sites in São Paulo, Brazil (N=880; from September 2016 to September 2017; final follow-up, April 2018), and in an individual-level RCT at 7 sites in Lima, Peru (N=432; from January 2017 to September 2017; final follow-up, March 2018). Interventions: An 18-session, low-intensity, digital intervention was delivered over 6 weeks via a provided smartphone, based on behavioral activation principles, and supported by nurse assistants (n = 440 participants in 10 clusters in São Paulo; n = 217 participants in Lima) vs enhanced usual care (n = 440 participants in 10 clusters in São Paulo; n = 215 participants in Lima). Main Outcomes and Measures: The primary outcome was a reduction of at least 50% from baseline in PHQ-9 scores (range, 0-27; higher score indicates more severe depression) at 3 months. Secondary outcomes included a reduction of at least 50% from baseline PHQ-9 scores at 6 months. Results: Among 880 patients cluster randomized in Brazil (mean age, 56.0 years; 761 [86.5%] women) and 432 patients individually randomized in Peru (mean age, 59.7 years; 352 [81.5%] women), 807 (91.7%) in Brazil and 426 (98.6%) in Peru completed at least 1 follow-up assessment. The proportion of participants in São Paulo with a reduction in PHQ-9 score of at least 50% at 3-month follow-up was 40.7% (159/391 participants) in the digital intervention group vs 28.6% (114/399 participants) in the enhanced usual care group (difference, 12.1 percentage points [95% CI, 5.5 to 18.7]; adjusted odds ratio [OR], 1.6 [95% CI, 1.2 to 2.2]; P = .001). In Lima, the proportion of participants with a reduction in PHQ-9 score of at least 50% at 3-month follow-up was 52.7% (108/205 participants) in the digital intervention group vs 34.1% (70/205 participants) in the enhanced usual care group (difference, 18.6 percentage points [95% CI, 9.1 to 28.0]; adjusted OR, 2.1 [95% CI, 1.4 to 3.2]; P < .001). At 6-month follow-up, differences across groups were no longer statistically significant. Conclusions and Relevance: In 2 RCTs of patients with hypertension or diabetes and depressive symptoms in Brazil and Peru, a digital intervention delivered over a 6-week period significantly improved depressive symptoms at 3 months when compared with enhanced usual care. However, the magnitude of the effect was small in the trial from Brazil and the effects were not sustained at 6 months. Trial Registration: ClinicalTrials.gov: NCT02846662 (São Paulo) and NCT03026426 (Lima).
Authors: Retha Arjadi; Maaike H Nauta; Willem F Scholte; Steven D Hollon; Neerja Chowdhary; Angela O Suryani; Cuno S P M Uiterwaal; Claudi L H Bockting Journal: Lancet Psychiatry Date: 2018-07-11 Impact factor: 27.083
Authors: Alyssa Sawyer; Amy Kaim; Huynh-Nhu Le; Denise McDonald; Murthy Mittinty; John Lynch; Michael Sawyer Journal: J Med Internet Res Date: 2019-06-04 Impact factor: 5.428
Authors: David Ekers; Lisa Webster; Annemieke Van Straten; Pim Cuijpers; David Richards; Simon Gilbody Journal: PLoS One Date: 2014-06-17 Impact factor: 3.240
Authors: Søren T Skou; Frances S Mair; Martin Fortin; Bruce Guthrie; Bruno P Nunes; J Jaime Miranda; Cynthia M Boyd; Sanghamitra Pati; Sally Mtenga; Susan M Smith Journal: Nat Rev Dis Primers Date: 2022-07-14 Impact factor: 65.038
Authors: Ana Basto-Abreu; Tonatiuh Barrientos-Gutierrez; Alisha N Wade; Daniela Oliveira de Melo; Ana S Semeão de Souza; Bruno P Nunes; Arokiasamy Perianayagam; Maoyi Tian; Lijing L Yan; Arpita Ghosh; J Jaime Miranda Journal: J Multimorb Comorb Date: 2022-06-16
Authors: V Cavero; M Toyama; H Castro; M T Couto; L Brandt; J Quayle; P R Menezes; D C Mohr; R Araya; J J Miranda; F Diez-Canseco Journal: Discov Ment Health Date: 2022-06-03
Authors: Carina Akemi Nakamura; Marcia Scazufca; Felipe Azevedo Moretti; Thiago Vinicius Nadaleto Didone; Mariana Mendes de Sá Martins; Luara Aragoni Pereira; Caio Hudson Queiroz de Souza; Gabriel Macias de Oliveira; Marcelo Oliveira da Costa; Marcelo Machado; Evelyn da Silva Bitencourt; Monica Souza Dos Santos; Jamie Murdoch; Pepijn van de Ven; Nadine Seward; William Hollingworth; Tim J Peters; Ricardo Araya Journal: Trials Date: 2022-09-07 Impact factor: 2.728
Authors: Mauricio Toyama; Victoria Cavero; Ricardo Araya; Paulo Rossi Menezes; David C Mohr; J Jaime Miranda; Francisco Diez-Canseco Journal: JMIR Hum Factors Date: 2022-09-15
Authors: Marcia Scazufca; Carina A Nakamura; Nadine Seward; Darío Moreno-Agostino; Pepijn van de Ven; William Hollingworth; Tim J Peters; Ricardo Araya Journal: Lancet Healthy Longev Date: 2022-10
Authors: Emily C Gathright; Katherine Diaz Vickery; Woubeshet Ayenew; Matthew C Whited; Melissa Adkins-Hempel; Michelle Chrastek; Jill K Carter; Rochelle K Rosen; Wen-Chih Wu; Andrew M Busch Journal: PLoS One Date: 2022-02-03 Impact factor: 3.240